IBRXImmunityBio, Inc.
Price
+285%1YEnd-of-day closes, not the intraday tick.
Survival is the story here: start there
Quality mixed, hard red flags, growing in the filings, the market undecided.
ImmunityBio, Inc. (“ImmunityBio,” the “Company,” “we,” “us,” or “our”) is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases. Our approach harnesses both the adaptive and innate immune systems with the goal of restoring immune function and generating lasting immunological memory in patients.
In the company’s own words · 10-K filed Feb 23, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
ImmunityBio, Inc. (IBRX) reported revenue of $51M in Q2 2026 (quarter ended Jun 30, 2026), up 94% from the same quarter a year earlier. That came with a gross margin of 99% and net loss of $230M. For the full year FY2025, revenue was $113M (+668% year on year) and net income −$351M. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 4, 2026Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million.Earnings release · press release
- Jul 30, 2026ImmunityBio Receives United Arab Emirates (UAE) Marketing.Regulation FD disclosure · press release
- May 18, 2026On May 14, 2026, ImmunityBio, Inc., a Delaware corporation (“ImmunityBio” or the “Company”), entered into an exclusive development and supply agreement (the “Agreement”) with Japan BCG Laboratory, a Japanese corporation (“JBL”)Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.